Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Zealand Pharma A/S ADR (NQ: ZEAL )

17.59 UNCHANGED
Last Price Updated: 3:24 PM EDT, Sep 29, 2022 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 0
Open 17.59
Bid (Size) 8.820 (2)
Ask (Size) 20.00 (2)
Prev. Close 17.59
Today's Range 17.59 - 17.59
52wk Range 9.930 - 20.49
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Zealand Pharma Hosts Conference Call on November 10 at 4pm CET (10am ET) to Present Third Quarter Results for 2022
From Zealand Pharma
Via Globe NewsWire
Zealand Pharma Announces Presentations at The Obesity Society Annual Meeting
From Zealand Pharma
Via Globe NewsWire

Performance

YTD
N/A
N/A
1 Month
N/A
N/A
3 Month
N/A
N/A
6 Month
+6.35%
+6.35%
1 Year
+27.33%
+27.33%

More News

Read More
Zealand Pharma major shareholder announcement: Polar Capital
From Zealand Pharma
Via Globe NewsWire
Zealand Pharma major shareholder announcement: Van Herk Investments
From Zealand Pharma
Via Globe NewsWire
Zealand Pharma's Dasiglucagon Aces Late-Stage Study In Pediatric Patients, Shares Move Higher
Via Benzinga
Recap: Zealand Pharma Q1 Earnings
Via Benzinga
Zealand Pharma completes registration of capital increase
From Zealand Pharma
Via Globe NewsWire
Zealand Pharma announces completion of a directed issue and private placement of 4,975,000 new ordinary shares raising gross proceeds of approx. DKK 786 million
From Zealand Pharma
Via Globe NewsWire
Zealand Pharma announces directed issue and private placement of approximately 4.5m new shares
From Zealand Pharma
Via Globe NewsWire
Novo Nordisk Touts Another Once-Weekly Insulin Icodec Win In Type 2 Diabetes
Via Benzinga
Total number of shares and voting rights in Zealand Pharma at September 30, 2022
From Zealand Pharma
Via Globe NewsWire
Zealand Pharma Announces Positive Results from Phase 3 Trial of Glepaglutide in Patients with Short Bowel Syndrome (EASE 1)
From Zealand Pharma
Via Globe NewsWire
Zealand Pharma, Novo Nordisk Ink Licensing Pact For Drug To Lower Blood Sugar Levels
Via Benzinga
Biotech Daily: Regulatory Setback For CorMedix, Mersana & GSK In Cancer Pact, BARDA Funding For Opioid Overdose Hopeful
Via Benzinga
Why Embark Technology Jumped Around 85%; Here Are 108 Biggest Movers From Friday
Via Benzinga
Why Twin Vee Powercats Is Trading Higher By Around 90%, Here Are 84 Stocks Moving In Friday's Mid-Day Session
Via Benzinga
The Daily Biotech Pulse: Thumbs Down For Acadia's Pimavanserin, Pfizer Buys Stake In Valneva, AstraZeneca - Ionis Eplontersen Aces Rare Disease Trial
Via Benzinga
71 Biggest Movers From Yesterday
Via Benzinga
Mid-Afternoon Market Update: Dow Falls 150 Points; NeuroMetrix Shares Spike Higher
Via Benzinga
38 Stocks Moving In Thursday's Mid-Day Session
Via Benzinga
Why Zealand Pharma Shares Are Rising
Via Benzinga
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Via Benzinga
The Daily Biotech Pulse: Pfizer-BioNTech's COVID-19 Booster For Kids 5-11 Coming Soon, Ultragenyx In-Licenses Gene Therapy For Genetic Disorder, Ampio's AP-013 Trial Under Independent Investigation
Via Benzinga
Stocks That Hit 52-Week Lows On Monday
Via Benzinga
The Daily Biotech Pulse: Bristol Myers, BridgeBio Ink Oncology Pact, FDA Nod For Lava Therapeutics Blood Cancer Study And More
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.